Amphastar Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products. The Company�s generic product candidates at various development stages that leverage its various technical capabilities, including injectable technologies, including various delivery methods and sizes of pre-filled syringes, vials in solution, suspension and lyophilized forms; inhalation technologies, including metered dose inhalers (MDIs) and metered dose inhalers (DPIs); and analytical technologies. As of May 20, 2014, the Company manufactures and sells 15 products in the United States and is developing a portfolio of 13 generic and seven injectable and inhalation product candidates. In addition to its marketed products, it has a pipeline of 20 generic and product candidates in various stages of development which target a variety of indications.